HKSE:02126 (China)
Â
Ordinary Shares
HK$
1.865
-0.035 (-1.84%)
Aug 18
Business Description
JW (Cayman) Therapeutics Co Ltd
ISIN : KYG5210T1040
Share Class Description:
HKSE:02126: Ordinary SharesTotal Employee Number:
314Compare
Compare
Traded in other countries / regions
02126.Hong KongJWCTF.USAJNY.Germany IPO Date
2020-11-03Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.92 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | -0.49 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -9.02 | |||||
Beneish M-Score | -4.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 23.8 | |||||
3-Year EBITDA Growth Rate | 15.9 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 50.7 | |||||
3-Year Book Growth Rate | -38.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 25.83 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.2 | |||||
9-Day RSI | 64.83 | |||||
14-Day RSI | 60.22 | |||||
3-1 Month Momentum % | -24.32 | |||||
6-1 Month Momentum % | -22.94 | |||||
12-1 Month Momentum % | -71.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.45 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 1.28 | |||||
Days Inventory | 175.12 | |||||
Days Sales Outstanding | 32.03 | |||||
Days Payable | 88.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 10.68 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.02 | |||||
Operating Margin % | -85.41 | |||||
Net Margin % | -195.54 | |||||
EBITDA Margin % | -190.44 | |||||
FCF Margin % | -27.57 | |||||
OCF Margin % | -26.99 | |||||
ROE % | -64.11 | |||||
ROA % | -41.28 | |||||
ROIC % | -23.98 | |||||
3-Year ROIIC % | -59.02 | |||||
ROC (Joel Greenblatt) % | -224.86 | |||||
ROCE % | -59.65 | |||||
Moat Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.46 | |||||
PB Ratio | 1.26 | |||||
Price-to-Tangible-Book | 1.96 | |||||
EV-to-EBIT | -0.79 | |||||
EV-to-EBITDA | -0.79 | |||||
EV-to-Revenue | 1.51 | |||||
EV-to-FCF | -5.49 | |||||
Price-to-GF-Value | 0.45 | |||||
| Price-to-Net-Current-Asset-Value | 5.04 | |||||
| Price-to-Net-Cash | 9.82 | |||||
Earnings Yield (Greenblatt) % | -126.58 | |||||
FCF Yield % | -10.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JW (Cayman) Therapeutics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 312.117 | ||
| EPS (TTM) (HK$) | -1.473 | ||
| Beta | 2.1517 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.23 | ||
| Volatility % | 39.57 | ||
| 14-Day RSI | 60.22 | ||
| 14-Day ATR (HK$) | 0.113475 | ||
| 20-Day SMA (HK$) | 1.7025 | ||
| 12-1 Month Momentum % | -71.48 | ||
| 52-Week Range (HK$) | 1.4 - 6.35 | ||
| Shares Outstanding (Mil) | 416.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JW (Cayman) Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JW (Cayman) Therapeutics Co Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
JW (Cayman) Therapeutics Co Ltd Frequently Asked Questions
What is JW (Cayman) Therapeutics Co Ltd(HKSE:02126)'s stock price today?
The current price of HKSE:02126 is HK$1.87. The 52 week high of HKSE:02126 is HK$6.35 and 52 week low is HK$1.40.
When is next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126)?
The next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126) is .
Does JW (Cayman) Therapeutics Co Ltd(HKSE:02126) pay dividends? If so, how much?
JW (Cayman) Therapeutics Co Ltd(HKSE:02126) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on JW (Cayman) Therapeutics Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers